Jesper Hastrup Svendsen is a Clinical Professor of Cardiology and Head of Department at the Department of Clinical Medicine. Dr. Svendsen is affiliated with the Heart Center at Copenhagen University Hospital – Rigshospitalet as a consultant. He graduated from the University of Copenhagen as a medical doctor (MD) in 1983 and earned his Doctor of Medical Sciences (DMSc; dr.med.) in 1994. He is a board-certified specialist in General Internal Medicine and Cardiovascular Diseases (Cardiology).

Dr. Svendsen’s research is primarily focused on cardiac arrhythmias. His areas of interest include atrial fibrillation, ion channel diseases, genetics in arrhythmia, inflammation in arrhythmia, Arrhythmogenic Right Ventricular Cardiomyopathy, ICD treatment, CRT (Cardiac Resynchronisation Therapy; biventricular pacing) of heart failure, catheter ablation, and ECG analysis. In his clinical work, Dr. Svendsen primarily takes care of patients with cardiac arrhythmia diseases. He has expertise in implantation and control of patients with cardiovascular implantable electronic devices (pacemakers, ICDs, and CRTs).  Besides the invasive treatment of cardiac arrhythmia patients, he has expertise in their pharmacological antiarrhythmic treatment

Potential conflicts of interests:

• Munksgaard (publisher): Dr. Svendsen is author in several editions (MK16 – 20) of Medicinsk Kompendium (a major Danish textbook) and editor of MK19, and in the editorial group of MK20.
• Swiss Re (reinsurance company): Dr. Svendsen serves as consultant
• Medtronic (device company): Dr. Svendsen serves in an advisory board
• Vital Beats (software company): Dr. Svendsen serves in an advisory board

Research funds:

Dr. Svendsen serves as member of board or member of advisory committee in Fabrikant Ulrik Brinch og hustru Marie Brinchs Legat; Fondsbørsvekselerer Henry Hansen og hustru Karla Hansen født Westergaards legat; Fru Gudrun Elboth, født Døbelins, Mindelegat; Kong Christian den Tiendes Fond; Ketty og Ejvind Lyngsbæks Fond; Fonden af 17-12-1981, Aase og Ejnar Danielsens Fond.

Research funding obtained from:

The SafeHeart study was supported by the European Union funding program for research and innovation for the Horizon 2020 (grant number: Eurostars project E!113994- SafeHeart) and Rigshospital Research Fund, Copenhagen University Hospital- Rigshospitalet, Copenhagen, Denmark.

The LOOP Study was supported by Innovation Fund Denmark [grant number 12-1352259], The Research Foundation for the Capital Region of Denmark, The Danish Heart Foundation [grant number 11-04-R83-A3363-22625], Aalborg University Talent Management Program, Arvid Nilssons Fond, Skibsreder Per Henriksen, R og Hustrus Fond, the European Union’s Horizon 2020 program [grant number 847770 to the AFFECT-EU consortium], Læge Sophus Carl Emil Friis og hustru Olga Doris Friis’ Legat, and an unrestricted grant from Medtronic.

Travel Grants from:

• Abbott, Medtronic and Biotronik
• Previous speaker fee from Medtronic, Biotronik, Boehringer Ingelheim, Novo Nordisk, Bayer og AstraZeneca